Domov › Burkittov limfom › Kansas
Klinične študije za Burkittov limfom v Kansas
6 študij za Burkittov limfom išče udeležence na lokacijah v Kansas.
Mesta v Kansas
Uradno besedilo študije (angleško)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
- Cancer Center of Kansas - Wichita, Wichita
Vključevanje udeležencevFaza 3
Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Wesley Medical Center, Wichita
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Mercy Hospital, Kansas City
Vključevanje udeležencevFaza 2
Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- in še 1
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT07069699Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
- University of Kansas Cancer Center, Westwood
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 14. maj 2026 · NCT06879340Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.